000137747 001__ 137747
000137747 005__ 20240321220315.0
000137747 0247_ $$2doi$$a10.1016/j.pbb.2014.11.006
000137747 0247_ $$2pmid$$apmid:25449360
000137747 0247_ $$2ISSN$$a0091-3057
000137747 0247_ $$2ISSN$$a1873-5177
000137747 0247_ $$2altmetric$$aaltmetric:4522453
000137747 037__ $$aDZNE-2020-04069
000137747 041__ $$aEnglish
000137747 082__ $$a540
000137747 1001_ $$0P:(DE-2719)2810406$$aSchneider, F.$$b0$$eFirst author$$udzne
000137747 245__ $$aEffects of methylphenidate on the behavior of male 5xFAD mice.
000137747 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2015
000137747 264_1 $$2Crossref$$3print$$bElsevier BV$$c2015-01-01
000137747 3367_ $$2DRIVER$$aarticle
000137747 3367_ $$2DataCite$$aOutput Types/Journal article
000137747 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705937368_13657
000137747 3367_ $$2BibTeX$$aARTICLE
000137747 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137747 3367_ $$00$$2EndNote$$aJournal Article
000137747 520__ $$aAlzheimer's disease is a neurodegenerative disorder characterized by a loss of memory and spatial orientation. It is also reported that the dopamine system is affected. Dopamine plays a prominent role in motor functions, motivation, emotion, arousal and reward, and it is important for learning and memory. One model that represents characteristic hallmarks of Alzheimer's disease is the 5xFAD mouse model, in which parenchymal plaque load starts at 2months of age. Transgenic 5xFAD mice show the first behavioral deficits at 6months, which are evident at 9months of age. In this study, we investigated the pharmacological influence of methylphenidate (MPH) on behavioral deficits of 5xFAD mice. Using a battery of behavioral tests, we observed no influence of MPH on anxiety in the elevated plus maze, whereas the locomotion and explorative activity in the open field was increased in transgenic and non-transgenic 5xFAD mice after the application of MPH. Further MPH inhibits habituation in the open field in healthy 5xFAD littermates after the application of 10mg/kg MPH. On the other hand, 10mg/kg MPH improved spatial memory in 6-month-old transgenic 5xFAD males, i.e., at a time point when deficits start to occur. However, in 9-month-old transgenic mice, MPH did not improve persisting learning and memory deficits. We concluded that MPH might improve the non-cognitive, apathy-like behavior (indicated by a reduced exploration), but it has no influence on sustained Alzheimer typical learning and memory deficits.
000137747 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000137747 542__ $$2Crossref$$i2015-01-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000137747 588__ $$aDataset connected to CrossRef, PubMed,
000137747 650_7 $$2NLM Chemicals$$aAmyloid beta-Protein Precursor
000137747 650_7 $$2NLM Chemicals$$aCentral Nervous System Stimulants
000137747 650_7 $$2NLM Chemicals$$aMutant Proteins
000137747 650_7 $$2NLM Chemicals$$aPSEN1 protein, human
000137747 650_7 $$2NLM Chemicals$$aPresenilin-1
000137747 650_7 $$0207ZZ9QZ49$$2NLM Chemicals$$aMethylphenidate
000137747 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000137747 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000137747 650_2 $$2MeSH$$aAlzheimer Disease: psychology
000137747 650_2 $$2MeSH$$aAmyloid beta-Protein Precursor: genetics
000137747 650_2 $$2MeSH$$aAnimals
000137747 650_2 $$2MeSH$$aAnxiety: drug therapy
000137747 650_2 $$2MeSH$$aBehavior, Animal: drug effects
000137747 650_2 $$2MeSH$$aBehavior, Animal: physiology
000137747 650_2 $$2MeSH$$aCentral Nervous System Stimulants: pharmacology
000137747 650_2 $$2MeSH$$aDisease Models, Animal
000137747 650_2 $$2MeSH$$aExploratory Behavior: drug effects
000137747 650_2 $$2MeSH$$aHabituation, Psychophysiologic: drug effects
000137747 650_2 $$2MeSH$$aHumans
000137747 650_2 $$2MeSH$$aMale
000137747 650_2 $$2MeSH$$aMaze Learning: drug effects
000137747 650_2 $$2MeSH$$aMethylphenidate: pharmacology
000137747 650_2 $$2MeSH$$aMice
000137747 650_2 $$2MeSH$$aMice, Transgenic
000137747 650_2 $$2MeSH$$aMotor Activity: drug effects
000137747 650_2 $$2MeSH$$aMutant Proteins: genetics
000137747 650_2 $$2MeSH$$aPresenilin-1: genetics
000137747 7001_ $$0P:(DE-2719)2239681$$aBaldauf, K.$$b1$$eCorresponding author$$udzne
000137747 7001_ $$0P:(DE-HGF)0$$aWetzel, W.$$b2
000137747 7001_ $$0P:(DE-2719)2740485$$aReymann, Klaus$$b3$$eLast author$$udzne
000137747 77318 $$2Crossref$$3journal-article$$a10.1016/j.pbb.2014.11.006$$b : Elsevier BV, 2015-01-01$$p68-77$$tPharmacology Biochemistry and Behavior$$v128$$x0091-3057$$y2015
000137747 773__ $$0PERI:(DE-600)2008734-2$$a10.1016/j.pbb.2014.11.006$$gVol. 128, p. 68 - 77$$p68-77$$q128<68 - 77$$tPharmacology, biochemistry and behavior$$v128$$x0091-3057$$y2015
000137747 8564_ $$uhttps://pub.dzne.de/record/137747/files/DZNE-2020-04069_Restricted.pdf
000137747 8564_ $$uhttps://pub.dzne.de/record/137747/files/DZNE-2020-04069_Restricted.pdf?subformat=pdfa$$xpdfa
000137747 909CO $$ooai:pub.dzne.de:137747$$pVDB
000137747 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810406$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000137747 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2239681$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000137747 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2740485$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000137747 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000137747 9141_ $$y2015
000137747 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000137747 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACOL BIOCHEM BE : 2017
000137747 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137747 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137747 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137747 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000137747 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000137747 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000137747 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000137747 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137747 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137747 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000137747 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137747 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000137747 9201_ $$0I:(DE-2719)1310005$$kAG Reymann$$lPathophysiology of Dementia$$x0
000137747 9201_ $$0I:(DE-2719)1340016$$kCore MR PET$$lCore MR PET$$x1
000137747 980__ $$ajournal
000137747 980__ $$aVDB
000137747 980__ $$aI:(DE-2719)1310005
000137747 980__ $$aI:(DE-2719)1340016
000137747 980__ $$aUNRESTRICTED